首页> 外文期刊>Applied immunohistochemistry and molecular morphology: AIMM >Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.
【24h】

Utility of cytokeratin 5/6, cytokeratin 20, and p16 in the diagnosis of reactive urothelial atypia and noninvasive component of urothelial neoplasia.

机译:细胞角蛋白5/6,细胞核酸素20和P16在尿路上皮瘤的非侵入性组分诊断中的效用。

获取原文
获取原文并翻译 | 示例
           

摘要

The utility of cytokeratin (CK)5/6 in distinguishing reactive urothelial atypia (RA) from urothelial carcinoma in situ (CIS) and from noninvasive component of high-grade papillary urothelial carcinoma (PUC) is unknown.Twenty RA with or without papillary hyperplasia and 90 noninvasive components of neoplastic urothelial lesions were submitted for immunostaining with CK5/6, CK20, and p16.Diffuse and strong reactivity involving the full or nearly full thickness of urothelium was observed with CK5/6 in 90% of RA cases. CK20 and p16 were negative in 90% and 85% of the RA cases, respectively. For CIS and noninvasive components of high-grade PUC without squamous differentiation, there was no CK5/6 staining or reactivity in the basal layer only. CK20 and p16 showed strong positivity in full thickness of urothelium in 75% to 85% of cases. CIS with weak/focal or negative reactivity for p16 or CK20 exhibited moderate cytologic atypia. Low-grade PUC displayed variable reactivity for CK5/6, CK20, and p16. Urothelial lesions with squamoid or basaloid features showed positive reactivity for CK5/6. Urothelial lesions with glandular differentiation showed negative reactivity for CK5/6.Diffuse CK5/6 reactivity in RA and negative CK5/6 reactivity in CIS and PUC may be helpful in distinguishing between these 2 entities.
机译:在原位(顺式)和高级乳头状尿道癌(PUC)原位(CIS)与尿路上皮癌中的反应性尿路上的Atypia(RA)与高等级乳头状尿尿癌(PUC)的非侵入性成分的效用是未经乳腺增生的影响。和90种肿瘤尿路上位病变的非侵入性成分被提交用于CK5 / 6,CK20和P16.DIFFUSE和涉及全部或接近全厚度的尿素的强的反应性,CK5 / 6在90%的RA病例中观察到CK5 / 6。 CK20和P16分别为80%和85%的RA病例。对于无鳞状分化的高级PUC的顺式和非侵入性成分,仅在基层中没有CK5 / 6染色或反应性。 CK20和P16在75%至85%的病例中显示出尿溶质的全厚度强的强度。对于P16或CK20的弱/焦虑或负反应性具有弱/焦虑或负反应性,表现出中度细胞学缺剂。低级PUC显示CK5 / 6,CK20和P16的可变反应性。含有Quaphaid或无碱特征的尿路上位病变显示CK5 / 6的正反应性。具有腺分化的尿路上位病变显示CK5 / 6.DIFFUSES的负反应性,CK5 / 6反应性在RA和负CK5 / 6中的反应性,CIS和PUC中的反应性可能有助于区分这2个实体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号